

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Application No.

09/905,452

Filing Date:

July 12, 2001

First Named Inventor

Nasir, et al.

Group Art Unit

1641

Examiner Name

unassigned

Attorney Docket No.

01-661

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
DAD		4,444,879		Foster <i>et al.</i>	04-24-1984	RECEIVED OCT 15 2002 TECH CENTER 1600/2000
		4,835,100		Dixon <i>et al.</i>	05-30-1989	
		5,262,333		Heiman <i>et al.</i>	11-16-1993	
		5,380,825		Stenglein <i>et al.</i>	01-10-1995	
		5,427,960		Wang <i>et al.</i>	06-27-1995	
		5,976,820		Jolley <i>et al.</i>	11-02-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
DAD		WO	97/19950		Oxis International, Inc.	06-05-1997		

Examiner
Signature

[Handwritten Signature]

Date
Considered

3-12-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231


Please type a plus sign (+) inside this box

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<div style="text-align: center;">  </div>		<div style="text-align: center;"> Complete if Known </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application No.		09/905,452	
		Filing Date:		July 12, 2001	
		First Named Inventor		Nasir	
		Group Art Unit		1641	
		Examiner Name		unassigned	
Sheet	2	of	2	Attorney Docket No.	01-660

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
D.A.D.	X	LANGONE, J., et al., "Aflatoxin B ₁ : Specific Antibodies and Their-Use in Radioimmunoassay," <i>Cancer Institute</i> 56(3): 591-595, March 1976.	
D.A.D.	X	SIZARET, P., et al., "Detection of Aflatoxins and Related Metabolites by Radioimmunoassay," <i>JNCI</i> 69(6):1375-1381, December 1982.	
D.A.D.	X	WHITAKER, et al., "Variability Associated with Analytical Methods Used to Measure Aflatoxin in Agricultural Commodities," <i>Journal of AOAC International</i> 79(2):476-485, 1996.	
D.A.D.	X	WILSON, T., et al., "Use of the Mycosep Multifunctional Cleanup Column for Liquid Chromatographic Determination of Aflatoxins in Agricultural Products," <i>J. Assoc. Off. Anal. Chem.</i> 74(6):951-956, 1991.	
D.A.D.	X	NEWBERNE, P., et al., "Acute and Chronic Effects of Aflatoxin on the Liver of Domestic and Laboratory Animals: A Review," <i>Cancer Research</i> 29:236-250, January 1969.	
D.A.D.	X	TRUCKSESS, M., et al., "Immunoaffinity Column Coupled With Solution Fluorometry or Liquid Chromatography Postcolumn Derivatization for Determination of Aflatoxins in Corn, Peanuts, and Peanut Butter: Collaborative Study," <i>J. Assoc. Off. Anal. Chem.</i> 74(1):81-88, 1991.	
D.A.D.	X	WILD, C., et al., "Aflatoxin Detected in Human Breast Milk by Immunoassay," <i>Int. J. Cancer</i> 40:328-333, 1987.	
D.A.D.	X	TRUCKSESS, et al., "Multifunctional Column Coupled with Liquid Chromatography for Determination of Aflatoxins B ₁ , B ₂ , G ₁ , and G ₂ in Corn, Almonds, Brazil Nuts, Peanuts, and Pistachio Nuts: Collaborative Study," <i>Journal of AOAC International</i> 77(6):1512-1521, 1994.	
D.A.D.	X	CAMPBELL, T., et al., "Implication of Mycotoxins for Human Health," <i>J. Agr. Food Chem.</i> 22(6):1006-1015, 1974.	
D.A.D.	X	SEITZ, L., "Comparison of Methods for Aflatoxin Analysis by High-Pressure Liquid Chromatography," <i>Journal of Chromatography</i> 104:81-89, 1975.	
D.A.D.	X	ASAO, T., et al., "The Structures of Aflatoxins B and G ₁ ," <i>Journal of the American Chemical Society</i> 87(4):882-886, February 20, 1965.	
D.A.D.	X	MARAGOS, C., et al., "Fiber-optic Immunosensor for Mycotoxins," <i>Nat. Toxins</i> 7:371-376, 1999.	
D.A.D.	X	NASIR, M., et al., "Fluorescence Polarization: An Analytical Tool for Immunoassay and Drug Discovery," <i>Combinatorial Chemistry & High Throughput Screening</i> , 2:177-190, 1999.	
D.A.D.	X	HOLLADAY, S.D., "Preparation of Protein Conjugatable Aflatoxin Oxime Derivative from Significantly Reduced Starting Quantities," <i>Veterinary Human Toxicology</i> 31(6):526-527, 1989 (abstract only).	
D.A.D.	X	HOLLADAY, S.D., "Production of Specific antibody against aflatoxin M ₁ ," <i>Dissertations Abstracts International</i> 50(10):4298, 1990.	

Examiner Signature		Date Considered	3-12-03
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231